Skip to content
Screener

LivaNova LIVN Q4 2025 Annual earnings

Reported February 25, 2026 · Before market open

Revenue$360.9MBeat by $7.6M
EPS$0.86Beat by $0.06
Revenue estimate$353.3M
EPS estimate$0.80

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$381.1M
EPS estimate$1.04

Financials

Q4 2025

Income statement

See full
Revenue$360.9M+12.1%
Gross profit$239.8M+11.9%
Operating income$42.6M+15.0%

Balance sheet

See full
Cash & equivalents$635.6M-12.2%
Total debt$433.2M-35.9%
Total equity$1.2B-9.1%
Total assets$2.6B+4.0%

Cash flow

See full
Operating cash flow$82.4M+4.7%
CapEx$32.2M+210%
Free cash flow$50.2M-26.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.36B+33.6%
Enterprise value$3.16B+28.0%
P/S2.4×+0.4×

Profitability

See full
Gross margin67.7%-0.4pp
Operating margin14.4%+4.1pp
FCF margin12.5%+1.6pp

Returns & leverage

See full
Debt / equity0.4×-0.2×
Current ratio1.4×-1.5×

Segments

By segment

See full
Cardiopulmonary$206.6M+13.7%
Neuromodulation$152.7M+11.0%

By geography

See full
Rest of World$94.4M+10.9%
Europe$75.0M+21.7%

FAQ

When did LivaNova report Q4 2025 earnings?
LivaNova (LIVN) reported Q4 2025 earnings on February 25, 2026 before market open.
What were LivaNova's Q4 2025 revenue and EPS?
LivaNova reported revenue of $360.9M and eps of $0.86 for Q4 2025.
Did LivaNova beat estimates in Q4 2025?
Revenue beat the consensus estimate of $353.3M by $7.6M. EPS beat the consensus estimate of $0.80 by $0.06.
How did LivaNova's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12.2% from $321.8M a year earlier and eps grew 6.2% from $0.81.
Where can I find LivaNova's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001639691-26-000006) and the 10-K periodic report (0001639691-26-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.